B of A Securities Upgrades Akero Therapeutics (AKRO)
Fintel reports that on January 30, 2025, B of A Securities upgraded their outlook for Akero Therapeutics (NasdaqGS:AKRO) from Neutral to Buy. Analyst Price Forecast Suggests 23.34% Upside As of January 28,
The Akero Therapeutics Inc Rollercoaster: What’s Behind the Latest AKRO Stock Fluctuation?
Akero Therapeutics Inc (AKRO) stock saw a modest uptick, ending the day at $54 which represents a slight increase of $2.53 or 4.92% from the prior close of $51.47. The stock opened at $52.48 and touched a low of $51.
J.P. Morgan Keeps Their Buy Rating on Akero Therapeutics (AKRO)
J.P. Morgan analyst Eric Joseph maintained a Buy rating on Akero Therapeutics (AKRO – Research Report) on January 27 and set a price target of
Why Akero Therapeutics, Inc.’s (AKRO) Stock Is Up 97.52%
Akero Therapeutics, Inc.’s AKRO share price has surged by 97.52%, which has investors questioning if this is right time to sell.
Akero Therapeutics (NASDAQ:AKRO) Stock Price Up 4.8% on Analyst Upgrade
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) traded up 4.8% during mid-day trading on Wednesday after Morgan Stanley raised their price target on the stock from $46.00 to $96.00. Morgan Stanley currently has an overweight rating on the stock.
Akero Therapeutics upgraded to Buy from Neutral at BofA
BofA analyst Jason Zemansky upgraded Akero Therapeutics (AKRO) to Buy from Neutral with a $63 price target Invest with Confidence: Follow
Akero Therapeutic prices upsized stock offering of $350M
Clinical-stage company developing transformational treatments for patients with serious metabolic disease—Akero Therapeutics (NASDAQ:AKRO) priced of an upsized underwritten public offering of 5.33M shares at $48.
Zacks.com on MSN2d
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study
Shares of Akero Therapeutics AKRO skyrocketed 105.7% in a week after the company announced initial positive top line 96-week ...
bovnews3d
Akero Therapeutics Inc (AKRO) Stock: More Resilient Than It Appears
Akero Therapeutics Inc (AKRO) stock saw a modest uptick, ending the day at $51.71 which represents a slight increase of $25.53 or 97.52% from the prior close of $26.18. The stock opened at $57.26 and ...
89bio's Pegozafermin Is Now Gaining Momentum
Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.
Akero Therapeutics (NASDAQ:AKRO) Stock Price Expected to Rise, HC Wainwright Analyst Says
Akero Therapeutics (NASDAQ:AKRO – Get Free Report) had its target price raised by HC Wainwright from $50.00 to $72.00 in a ...